An interventional study of supervised lifestyle modification in Obesity Prevention, Obesity and Metabolic Disease, sponsored by Slovak Academy of Sciences. Active, not recruiting at 1 site in Slovakia. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by Slovak Academy of Sciences · Not applicable, Interventional, and Basic science
Among 34 studies in Obesity with a site in Slovakia — 9 open to participants now, 17 under way, 14 of them phase 3. Obesity · Slovakia.
Among the 34 studies in Obesity with a site in Slovakia, this one is the 31st largest by planned enrollment, is one of 2 that started in 2024, is one of 6 with no phase, reaches primary completion later than 1 of the 16 other live ones, and was the 19th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
This study's planned enrollment of 50 is below the median of 67 across 9,006 interventional studies indexed under Obesity.
Browse Obesity studies →9 of the 34 studies in Obesity with a site in Slovakia are open now, in 12 countries. Each count lists the studies.
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 20 Years to 50 Years · all sexes · no healthy volunteers.
The full table on the hub →34 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2024.
Median enrollment 632 across the 34 interventional studies. Of the 14 that completed or were terminated, 4 (29%) have results posted.
29 of 34 have an industry lead sponsor. The 10 most frequent:
Slovak Academy of Sciences is the lead sponsor of 13 studies on the registry; 3 are open to participants now.
Slovak Academy of Sciences has 5 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
4 of the studies in Obesity with a site in Slovakia that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07311850Phase 3PfizerEfficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity | 2027-09-21 |
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
Among the 34 studies in Obesity with a site in Slovakia, from their registry updates:
The goal of this clinical trial is to detect the impact of the 3-month complex lifestyle intervention, consisting of dietary counselling, supervised exercise training and cognitive-behavioural intervention in middle-aged sedentary individuals with obesity, specific questions are:
Researchers will examine effects of exercise training intervention on whole body energy metabolism, by integrating clinical, biochemical and molecular data.
Participants will:
Inclusion Criteria: 30-45 kg.m-2 -
Exclusion Criteria: smoking, cancer,
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: supervised lifestyle modification
Supervised lifestyle intervention will consist of regular exercise (3x a week), nutritional counselling (weekly), cognitive bahavioural therapy (monthly).
Metabolic flexibility in response to submaximal exercise and nutritional challenge
Metabolic flexibility (metabolic substrate switching) will be measured using indirect calorimetry during submaximal exercise test (on stationary bike) and in response to nutritional challenge (fasting / glucose uptake during oGTT)
Time frame: 24 months
cardiopulmonary fitness (VO2max)
Cardiopulmonary fitness will be measured by bicycle spiro-ergometry
Time frame: 24 months
Index of insulin resistance (oGTT)
Index of insulin resistance will be calculated from the results of the frequently sampled oral glucose tolerance test oGTT.
Time frame: 24 months
abdominal adiposity and abdominal adipose tissue distribution (subcutaneous / visceral)
abdominal adiposity will be assessed by quadrupedal biopimpedance, and adipose tissue distribution by magnetic resonance imagining
Time frame: 24 months
Plan to share: Yes — Study protocol and SAP will be available upon study completion, and primary and secondary outcomes (clinical study report) will be shared after publishing the results in a scientific journal.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: 06/2026 (start date) indefinitely (end date)
Access criteria: researchers with legitimate interest
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2025, 12 months after the start.
Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 12 months is below that.
Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Slovak Academy of Sciences